PERBEDAAN KADAR CALPROTECTIN DAN HUMAN BETA DEFENSIN 2 TINJA PADA NEONATUS PREMATUR YANG MENDAPAT ASI, SUSU FORMULA, DAN KOMBINASINYA
DOI:
https://doi.org/10.21776/ub.majalahkesehatan.2020.07.02.4Keywords:
human beta defensin 2, calprotectin, prematur, tinjaAbstract
Insiden enterokolitis nekrotikan (EKN) berkisar 1-5% dari setiap 1000 kelahiran hidup dengan angka kematian mencapai 20-30%. Pemberian nutrisi yang optimal dapat mengurangi masalah saluran cerna. Penelitian ini bertujuan mengetahui kadar calprotectin sebagai protein inflamasi dan human ß-defensin 2 (hBD-2) tinja sebgai peptida antimikroba pada neonatus prematur yang mengonsumsi ASI, susu formula, maupun ASI dan susu formula. Penelitian ini terdiri dari 39 sampel yang memenuhi kriteria inklusi terbagi ke dalam tiga kelompok yaitu neonatus prematur yang mengonsumsi ASI saja, susu formula saja, serta kombinasi ASI dan susu formula. Kadar calprotectin dan hBD-2 tinja diukur menggunakan metode ELISA. Hasil menunjukkan rerata kadar calprotectin tinja secara signifikan lebih rendah pada kelompok neonatus prematur yang mendapat ASI saja dibandingkan kelompok susu formula saja maupun kombinasi ASI dan susu formula (p=0,00). Rerata kadar hBD-2 tinja secara signifikan lebih rendah pada kelompok neonatus prematur yang mendapat ASI saja dibandingkan kelompok susu formula saja maupun kombinasi ASI dan susu formula (p = 0,00). Kesimpulannya, kadar calprotectin dan hBD-2 tinja neonatus prematur yang mengonsumsi ASI lebih rendah dibandingkan kelompok susu formula maupun kombinasi ASI dan susu formula.
Â
References
Soeorg H, Huik K, Parm U, Ilmoja ML, Metelskaja N, Metsvaht T, Lutsar I. 2013. Genetic relatedness of coagulase-negative staphylococci from gastrointestinal tract and blood of preterm neonates with late-onset sepsis. Pediatr Infect Dis J; 32: 389–393.
Frost B. 2014. Maternal breast milk transforming growth factor beta and feeding intolerance in preterm infants. Journal Pediatr Res; 76(4): 386–393.
Campeotto F, Butel MJ, Kalach N, Derrieux S, Aubert- Jacquin C, Barbot L. (2004). High fecal kalprotektin concentrations in newborn infants. Arch Dis Child Fetal Neonatal Ed; 89(4):F353–F355.
Vaos G, Kostakis ID, Zavras N, Chatzemichael A. (2013). The role of kalprotektin in pediatric disease. Biomed Res Int; 2013:542363.
Otte JM, Werner I, Brand S, Chromik AM, Schmitz F, Kleine M, Schmidt WE. (2008). Human beta defensin 2 Promotes Intestinal Wound Healing. Journal of Cellular Biochemistry 104: 2286—2297.
Arisanti D, Wibowo S. 2019. Fecal Calprotectin Level of Breast Milk-Formula vs Formula Feeding in Preterm and Low Birth Weight Neonates with Necrotizing Enterocolitis. Journal of Tropical Life Science; 9(1): 29—33.
Rugtveit J, Fagerhol MK. (2002). Age-dependent variations in fecal kalprotektin concentrations in children. J Pediatr Gastroenterol Nutr; 34(3):323–324
Kapel N, Campeotto F, Kalach N. (2010). Fecal kalprotektin in term and preterm babys. Journal of Gastroenterology Hepatology and Nutrition 51 (5): 542 – 547.
Asgarshirazi M, et al. (2017). Comparison of Fecal Clprotectin in Exclusively Breastfed and formula or Mixed Fed Infants in the First Six Months of Life. Acta Med Iran.
Dorosco SM, Mackenzie T, Connor I. (2008). Fecal kalprotektin concentrations are higher in exclusively breastfed infants compared to those who are mixed-fed. Breastfeed Med; 3(2):117-119.
Savino F, Castagno E, Calabrese R, Viola S, Oggero R, Miniero R. (2010). High faecal kalprotektin levels in healthy, exclusively breast-fed infants. Neonatology; 97(4):299–304.
Li F, MaJ, Geng S, Wang J, Ren F, Sheng X. (2014). Comparison of the different kinds of feeding on the level of fecal kalprotektin. Early Hum Dev; 90:471-5.
Rosti L, Braga M, Fulcieri C, Sammarco G, Manenti B, Costa E. (2011). Formula milk feeding does not increase the release of the inflammatory marker kalprotektin, compared to human milk. Pediatr Med Chir; 33:178- 81.
Campeotto F, Baldassarre M, Laforgia N, Viallon V, Kalach N, Amati L, Butel MJ, Dupont C, Kapel N. 2010. Fecal Expression of Human Beta Defensin 2 following Birth. Neonatology; 98:365—369.
Corebima B.I.R.V, Rohsiswanto R, Gayatri P, Patole S. (2019). Fecal human ï¢-defensin-2(hBD-2) levels and gut microbiota patters in preterm neonates with different feeding patterns. Iranian Journal of Microbiology; vol 11, 2:151-159.
Jenke AC, Zilbauer M, Postberg J, Wirth S. 2012. Human-defensin 2 expression in ELBW infants with severe necrotizing enterocolitis. Pediatr Res;72:513-20.
Rousias JG, Karagounis P, Parvulesku G, Legakis NJ, Tsakris A. 2010. In Vitro Bactericidal Activity of Human Beta Defensin 2 againts Nosocomial Strain. J.peptide; 31: 1654—1660.
Baricelli J, Rocafull MA, Vázquez D, Bastidas B, Báez-Ramirez E, Thomas LE. 2015. Beta-defensin-2 in breast milk displays a broad antimicrobial activity against pathogenic bacteria. J Pediatr (Rio J); 91:36—43.
